Revenue
2018
2019
2020
2021
2022
2023
2024
2025
ACCENDRA HEALTH INC/VA/ (ACH)
Price—Loading quote
Net income
2018
2019
2020
2021
2022
2023
2024
2025
Free cash flow
2018
2019
2020
2021
2022
2023
2024
2025
Total cash / debt
CashTotal debt
2018
2019
2020
2021
2022
2023
2024
2025
Financial statements
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 | 2008 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.76B | $2.68B | $2.55B | $9.96B | $9.79B | $8.48B | $9.21B | $9.42B | $9.32B | $9.72B | $9.77B | $9.44B | $9.07B | $8.87B | $8.63B | $8.12B | $8.04B | $7.24B |
| Gross profit | — | $2.22B | $2.13B | $1.83B | $1.51B | $1.28B | $1.13B | $1.07B | $1.17B | $1.19B | $1.21B | $1.17B | $1.12B | $924.7M | $857.5M | $807.7M | $814.4M | $741.1M |
| Research & development | — | $13.0M | $13.0M | $12.0M | $12.1M | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating expenses | $2.73B | $2.90B | $2.42B | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Operating income | $27.5M | −$217.7M | $133.2M | $142.9M | $368.5M | $204.1M | $73.2M | −$352.3M | $89.3M | $199.6M | $200.4M | $159.5M | $198.1M | $196.8M | $203.5M | $195.9M | $201.3M | $180.7M |
| EBITDAderived | $242.0M | −$36.4M | $343.6M | $371.6M | $459.1M | $297.5M | $189.8M | −$250.4M | $148.7M | $255.0M | $266.3M | $222.9M | $248.7M | $236.4M | $237.7M | $225.1M | $226.5M | $202.7M |
| Net income | −$1.10B | −$362.7M | −$41.3M | $22.4M | $221.6M | $29.9M | −$62.4M | −$437.0M | $72.8M | $108.8M | $103.4M | $66.5M | $110.9M | $109.0M | $115.2M | $110.6M | $104.7M | $93.3M |
| Basic EPSper diluted share | -$14.31 | -$4.73 | -$0.54 | $0.30 | $3.05 | $0.47 | -$1.03 | -$7.28 | $1.20 | $1.76 | $1.65 | $1.06 | $1.76 | $1.72 | $1.82 | $1.76 | $1.68 | $1.51 |
| Diluted EPSper diluted share | -$14.31 | -$4.73 | -$0.53 | $0.29 | $2.94 | $0.47 | -$1.03 | -$7.28 | $1.20 | $1.76 | $1.65 | $1.06 | $1.76 | $1.72 | $1.81 | $1.75 | $1.67 | $1.50 |
Insider buys & sells
| Transaction | Insider | Type | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| Aug 14, 2025Form 4 | COLISEUM CAPITAL PARTNERS, L.P. +4TenPercentOwner | BuyCommon Stock · indirect | 492.9K | $5.31 | $2.62M | 13.10M |
| Aug 13, 2025Form 4 | COLISEUM CAPITAL PARTNERS, L.P. +4TenPercentOwner | BuyCommon Stock · indirect | 325.0K | $5.46 | $1.77M | 12.61M |
| Aug 12, 2025Form 4 | COLISEUM CAPITAL PARTNERS, L.P. +4TenPercentOwner | BuyCommon Stock, par value $2 per share ("Common Stock") · indirect | 720.0K | $5.15 | $3.71M | 12.28M |
| Apr 10, 2025Form 4 | Coliseum Capital, LLC +4TenPercentOwner | BuyCommon Stock · indirect | 80.0K | $7.19 | $575.2K | 11.56M |
| Apr 9, 2025Form 4 | Coliseum Capital, LLC +4TenPercentOwner | BuyCommon Stock · indirect | 225.0K | $7.39 | $1.66M | 11.48M |